

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Actions and Directives

Consider taking an AI Rec_1: Cond_15: Act_17
consider taking an AI Rec_1: Cond_14: Act_16
consider tamoxifen for a duration of (5 years minus AI duration) years Rec_4: Cond_7: Act_8
discontinue AI after 5 years total endocrine therapy Rec_4: Cond_9: Act_10
treat with 5 years of tamoxifen as primary adjuvant endocrine therapy Rec_1: Cond_1: Act_1
clinicians may recommend that patients change treatment Rec_6: Cond_12: Act_13
consider adverse effects Rec_6: Cond_16: Act_18
consider patient preferences Rec_6: Cond_16: Act_19
consider pre-existing conditions Rec_6: Cond_16: Act_20
counsel about adverse effect profiles of tamoxifen and AI Rec_6: Cond_17: Act_21
may be advised to consider tamoxifen Rec_7: Cond_13: Act_14

may be advised to consider a different AI
Rec_7: Cond_13: Act_15